Lamdong Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Lamdong Pharmaceutical's earnings have been declining at an average annual rate of -16.8%, while the Pharmaceuticals industry saw earnings growing at 12.1% annually. Revenues have been declining at an average rate of 21.3% per year.
Key information
-16.8%
Earnings growth rate
-12.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 13.0% |
| Revenue growth rate | -21.3% |
| Return on equity | -14.6% |
| Net Margin | -7.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Lamdong Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 188,473 | -13,554 | 48,125 | 0 |
| 31 Dec 23 | 186,001 | -20,105 | 49,509 | 0 |
| 30 Sep 23 | 184,294 | -24,671 | 51,996 | 0 |
| 30 Jun 23 | 182,592 | -29,197 | 54,103 | 0 |
| 31 Mar 23 | 180,649 | -46,886 | 63,730 | 0 |
| 31 Dec 22 | 187,415 | -38,891 | 62,833 | 0 |
| 30 Sep 22 | 182,648 | 25,319 | 58,699 | 0 |
| 30 Jun 22 | 169,250 | 29,921 | 49,598 | 0 |
| 31 Mar 22 | 171,086 | 44,478 | 39,876 | 0 |
| 31 Dec 21 | 161,902 | 37,870 | 41,013 | 0 |
| 30 Sep 20 | 273,079 | -5,153 | 65,603 | 0 |
| 31 Mar 20 | 367,551 | 12,217 | 76,155 | 0 |
| 31 Dec 19 | 379,664 | 9,586 | 78,898 | 0 |
| 30 Sep 19 | 388,029 | -13,436 | 78,456 | 0 |
| 31 Mar 19 | 418,258 | -17,849 | 75,013 | 0 |
| 31 Dec 18 | 431,851 | -16,870 | 71,021 | 0 |
| 30 Sep 18 | 434,377 | -9,524 | 64,620 | 0 |
| 30 Jun 18 | 479,747 | -583 | 61,259 | 0 |
| 31 Mar 18 | 504,843 | 8,547 | 57,606 | 0 |
| 31 Dec 17 | 528,312 | 14,625 | 56,135 | 0 |
| 30 Sep 17 | 549,702 | 19,674 | 59,909 | 0 |
| 30 Jun 17 | 523,947 | 19,413 | 56,313 | 0 |
| 31 Mar 17 | 519,324 | 19,825 | 56,063 | 0 |
| 31 Dec 16 | 513,510 | 19,767 | 54,771 | 0 |
| 30 Sep 16 | 517,804 | 19,720 | 51,593 | 0 |
| 30 Jun 16 | 505,139 | 18,855 | 50,033 | 0 |
| 31 Mar 16 | 498,619 | 18,181 | 45,368 | 0 |
| 31 Dec 15 | 484,278 | 17,682 | 42,912 | 0 |
| 30 Sep 15 | 493,299 | 16,732 | 40,267 | 0 |
| 30 Jun 15 | 480,521 | 17,101 | 38,378 | 0 |
| 31 Mar 15 | 476,675 | 18,175 | 38,085 | 0 |
| 31 Dec 14 | 484,310 | 18,582 | 39,266 | 0 |
| 30 Sep 14 | 459,306 | 18,622 | 37,418 | 0 |
| 30 Jun 14 | 469,223 | 18,770 | 40,172 | 0 |
| 31 Mar 14 | 463,778 | 18,095 | 40,710 | 0 |
| 01 Jan 14 | 462,895 | 18,007 | 39,312 | 0 |
| 30 Sep 13 | 454,939 | 19,853 | 37,465 | 0 |
| 30 Jun 13 | 438,973 | 20,322 | 34,823 | 0 |
Quality Earnings: LDP is currently unprofitable.
Growing Profit Margin: LDP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LDP is unprofitable, and losses have increased over the past 5 years at a rate of 16.8% per year.
Accelerating Growth: Unable to compare LDP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LDP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.6%).
Return on Equity
High ROE: LDP has a negative Return on Equity (-14.65%), as it is currently unprofitable.